Short Courses
Your registration to the ASDP Virtual Annual Meeting includes admission to the Short Courses.
- Short Course I
Utilizing Newer Tools for Longstanding Conundrums: Ancillary Diagnostic Testing
- Short Course II
Cutaneous T-cell Lymphomas: New Directions and Old Challenges
- Short Course III
Nails! Overcoming Challenges in this Important and Sometimes Problematic Area of Dermatology and Dermatopathology
- Short Course IV
Diversity in Dermatopathology
Short Course I
Utilizing Newer Tools for Longstanding Conundrums: Ancillary Diagnostic Testing
Thursday, October 20
1:00 p.m. - 3:30 p.m. CT
(Virtual)
Course Director
Emily Y. Chu, MD, PhD
Perelman School of Medicine at the University of Pennsylvania
2.5 AMA PRA Category 1 CreditsTM
An increasing number of ancillary diagnostic techniques have been developed in recent years, and may be helpful adjuncts in longstanding clinical conundrums. In this course, several tests intended to aid in the diagnosis of difficult melanocytic lesions, cutaneous lymphomas, and soft tissue neoplasms will be discussed. Scientific principles, appropriate clinical scenarios and other practical considerations of these ancillary tests will also be reviewed, including anticipated cost and turnaround time.
Faculty and Course Outline:
| 1:00 p.m. – 1:05 p.m. CT |
Introductions
Emily Y. Chu, MD PhD
Perelman School of Medicine at the University of Pennsylvania
|
| 1:05 p.m. – 1:35 p.m. CT |
T-cell Clonality Assessment for Cutaneous Lymphomas
Kerri E. Rieger, MD PhD
Stanford University
|
| 1:35 p.m. – 2:05 p.m. CT |
Incorporation of Next Generation Sequencing for Diagnosis of Difficult
Melanocytic Lesions
Jeffrey North, MD
University of California, San Francisco
|
| 2:05 p.m. – 2:35 p.m. CT |
Identifying Gene Fusions in Spitz Neoplasms: Which Test is Best?
Pedram Gerami, MD
Northwestern University
|
| 2:35 p.m. – 3:00 p.m. CT |
Molecular Testing for Soft Tissue Tumors
Steven D. Billings, MD
Cleveland Clinic
|
| 3:00 p.m. – 3:30 p.m. CT |
Q&A, Closing Remarks & Announcements |
Learning Objectives
Upon completion of this course, participants should be able to:
- Utilize appropriate ancillary molecular tests to aid in the diagnosis of difficult melanocytic lesions, cutaneous lymphomas, and soft tissue neoplasms.
- Identify clinical scenarios in which additional diagnostic testing is most useful.
Short Course II
Cutaneous T-cell Lymphomas: New Directions and Old Challenges
Friday, October 21
8:00 a.m. - 12:00 p.m. CT
(Virtual)
Course Director
Alexandra C. Hristov, MD
University of Michigan
3.5 AMA PRA Category 1 CreditsTM
This course will focus on pearls and pitfalls in the diagnosis of cutaneous T-cell lymphomas with a special emphasis on new concepts. It will begin with a discussion of dermatitis/reactive mimickers of mycosis fungoides (MF), including drug reactions and chronic spongiotic dermatitis, and new considerations in this differential diagnosis. The course will then turn to examine cases of MF that may mimic dermatitis/reactive processes and how these cases can be recognized, followed by primary cutaneous gamma delta T-cell lymphoma. There have been recent challenges to the traditional understanding of this lymphoma and this lecture will address updates, remaining questions, and tools to aid in differentiating this lymphoma from other lymphomas and lymphoproliferative disorders. Next, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma will be reviewed, including tips on how this entity can be distinguished from MF, recent suggested modifications to the diagnostic criteria and developments in our understanding of the genetics of this lymphoma. Lastly, this course will conclude with a discussion of lymphomatoid papulosis (LyP) with a review of more recently recognized variants of LyP as well as LyP occurring in unusual locations.
Faculty and Course Outline:
| 8:00 a.m. – 8:05 a.m. CT |
Introductions
Alexandra C. Hristov, MD
University of Michigan
|
| 8:05 a.m. – 8:40 a.m. CT |
Dermatitis/Reactive Mimickers of Mycosis Fungoides
Catherine Chung, MD
Ohio State University
|
| 8:40 a.m. – 9:15 a.m. CT |
Mycosis Fungoides Mimicking Dermatitis
Nneka Comfere, MD
Mayo Clinic
|
| 9:15 a.m. – 9:50 a.m. CT |
Primary Cutaneous Gamma Delta T-cell Lymphoma
Joan Guitart, MD
Northwestern University
|
| 9:50 a.m. – 10:05 a.m. CT |
Q&A |
| 10:05 a.m. – 10:35 a.m. CT |
Break |
| 10:35 a.m. – 11:10 a.m. CT |
Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma
Christiane Querfeld, MD, PhD
City of Hope
|
| 11:10 a.m. – 11:45 a.m. CT |
Lymphomatoid Papulosis
Antonio Subtil Deoliveira, MD, MBA
Royal Jubilee Hospital
|
| 11:45 a.m. – Noon CT |
Q&A, Closing Remarks & Announcements |
Learning Objectives
Upon completion of this course, participants should be able to:
- Differentiate between mycosis fungoides and its separation from dermatitis, and other new entities that can mimic or unmask mycosis fungoides.
- Evaluate changes in our understanding of primary cutaneous gamma delta T-cell lymphoma and its differential diagnosis.
- Describe primary cutaneous CD8+ aggressive epidermotropic cytotoxic lymphoma and identify recent developments in our understanding of the genetic background of this lymphoma.
- Identify new variants of lymphomatoid papulosis and lymphomatoid papulosis at unusual sites.
Short Course III
Nails! Overcoming Challenges in this Important and Sometimes Problematic Area of Dermatology and Dermatopathology
Saturday, October 22
8:00 a.m. – 12:00 p.m. CT
(In-person & live-streamed)
Course Director
Adam I. Rubin, MD
Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia
Perelman School of Medicine at the University of Pennsylvania
3.5 AMA PRA Category 1 CreditsTM
Interpretation of nail unit specimens can be challenging for any dermatopathologist. Difficulties in all steps leading to an eventual diagnosis, may include orientation of tissue, grossing, softening the nail plate that may be too hard to cut, the nail tissue sticking to slides, as well as conveying histopathologic findings in the clinical context of the unique nail anatomy.
This year’s Short Course III will discuss up-to-date diagnostic features of essential areas of nail unit disorders, and provide tips on collaboration with clinicians to deliver outstanding patient care and optimize outcomes.
Faculty and Course Outline:
| 8:00 a.m. – 8:30 a.m. CT |
Basic to Advanced Nail Surgery for the Dermatopathologist
Nathaniel Jellinek, MD
Brown Medical School
|
| 8:30 a.m. – 9:00 a.m. CT |
Grossing and Preparation of Nail Unit Specimens: From Nail Clippings to Amputations and Everything in Between
Curtis T. Thompson, MD
CTA Pathology and Oregon Health and Sciences University
|
| 9:00 a.m. – 9:30 a.m. CT |
Diagnosis of “Onycho” Tumors: How to Recognize and Diagnose Nail Specific Tumors with Clinical Integration
Eckart D. Haneke, MD, PhD
Inselspital, Universitätsspital Bern
|
| 9:30 a.m. – 10:00 a.m. CT |
Clinical and Histopathologic Features of Inflammatory and Infectious Nail Unit Disorders
Molly A. Hinshaw, MD
University of Wisconsin
|
| 10:00 a.m. – 10:30 a.m. CT |
Break |
| 10:30 a.m. - 10:45 a.m. CT |
Q&A |
| 10:45 a.m. – 11:15 a.m. CT |
Achieving Accurate Diagnosis of Pediatric Melanonychia
Beth S. Ruben, MD
Sutter Health
|
| 11:15 a.m. – 11:45 a.m. CT |
Diagnostic Pitfalls of Nail Unit Melanoma
Adam I. Rubin, MD
University of Pennsylvania and the Children’s Hospital of Philadelphia
|
| 11:45 a.m. – Noon CT |
Q&A, Closing Remarks & Announcements |
Learning Objectives
Upon completion of this course, participants should be able to:
- Diagnose a variety of nail specimens which may be submitted to a dermatopathology laboratory from a clinician.
- Apply ideal grossing and preparation methods for nail specimens submitted to a dermatopathology laboratory.
- Evaluate the histopathologic diagnostic features of nail unit specific tumors, inflammatory and infectious disorders, and their respective clinical findings.
- Demonstrate greater understanding of histopathologic diagnostic findings in pediatric melanonychia and nail unit melanoma.
Short Course IV
Game Changers in Dermatopathology
Sunday, October 23
8:00 a.m. – 12:00 p.m. CT
(In-person & live-streamed; with audience response in person)
Course Director
Alina G. Bridges, DO, FAAD
Donald and Barbara Zucker School of Medicine at Hofstra; Northwell Health, New York
3.5 AMA PRA Category 1 CreditsTM
This interactive course will feature a diverse group of panelists sharing updates on what’s new in dermatopathology through review of best practice guidelines, literature reviews, and evidence-based medical resources. The course will be comprised of four panels, and each panel will share practice pearls to aid dermatopathologists maneuver potential pitfalls:
- Panel 1 will cover practical strategies to improve the dermatopathology report while providing clear diagnostic and prognostic information to guide patient management under the 21st Century Cures Act, along with risk management and medical legal prospective.
- Panel 2 will discuss what’s new in dermatopathology, another immunohistochemistry (IHC) stain - beyond IHC
- Panel 3 will focus on the molecular era in dermatopathology; the current paradigm for the diagnosis of indeterminant melanocytic lesions using appropriate molecular testing; Prognostic testing for melanoma.
- Panel 4 will undertake the digital era in dermatopathology. What does it take to make a transition of clinical and academic activities into remote digital pathology without major workflow disruptions and how to accomplish it; deep learning/artificial intelligence in dermatopathology - friend or foe?
Faculty and Course Outline:
| 8:00 a.m. – 8:05 a.m. CT |
Introductions
Alina G. Bridges, DO
Donald and Barbara Zucker School of Medicine at Hofstra; Northwell Health, New York
|
| 8:05 a.m. – 8:50 a.m. CT |
Panel 1
Antoanella Calame, MD, FAAD
Compass Dermatopathology
Emily Y. Chu, MD, PhD
Perelman School of Medicine at the University of Pennsylvania
Ruifeng Guo, MD, PhD
Mayo Clinic, Rochester
Whitney A. High, MD, JD
University of Colorado, Denver
|
| 8:50 a.m. – 9:35 a.m. CT |
Panel 2
Karen Fritchie, MD
Cleveland Clinic, Cleveland
Ruifeng Guo, MD, PhD
Mayo Clinic, Rochester
Cecilia Lezcano, MD
Memorial Sloan Kettering Cancer Center, New York
|
| 9:35 a.m. – 9:45 a.m. CT |
Q&A
|
| 9:45 a.m. – 10:15 a.m. CT |
Break |
| 10:15 a.m. - 11:00 a.m. CT |
Panel 3
Alina G. Bridges, MD
Zucker School of Medicine, Northwell Health
Aleodor Andea, MD
University of Michigan, Ann Arbor
Iwei Yeh, MD, PhD
University of California, San Francisco
Emily Y. Chu, MD, PhD
Perelman School of Medicine at the University of Pennsylvania
|
| 11:00 a.m. – 11:45 a.m. CT |
Panel 4
Silvija Gottesman, MD
Zucker School of Medicine, Northwell Health
Rajendra Singh, MD
Summit Health
Limin Yu, MD
PathAI, Boston
|
| 11:45 a.m. – Noon CT |
Q&A, Closing Remarks & Announcements |
Learning Objectives
Upon completion of this course, participants should be able to:
- Implement best practice guidelines to improve current practice standards using findings from literature reviews and evidence-based medicine resources.
- Demonstrate greater understanding of new diagnostic and prognostic molecular testing, immunohistochemistry, and digital pathology.
- Apply risk management and medical legal practice pearls derived from the experience of expert dermatopathologists.
- Utilize practical strategies to improve dermatopathology reports by providing clear diagnostic and prognostic information to guide patient management under the 21st Century Cures Act will be presented.